GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 107 filers reported holding GENMARK DIAGNOSTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $3,082,000 | -1.4% | 211,086 | -4.1% | 0.11% | -21.7% |
| Q3 2020 | $3,126,000 | -10.2% | 220,108 | -7.0% | 0.14% | -17.4% |
| Q2 2020 | $3,480,000 | +11.5% | 236,557 | -68.8% | 0.17% | -17.3% |
| Q1 2020 | $3,122,000 | +10.1% | 757,878 | +28.6% | 0.20% | +51.9% |
| Q4 2019 | $2,835,000 | +11.5% | 589,313 | +40.4% | 0.13% | +1.5% |
| Q3 2019 | $2,543,000 | +27.5% | 419,673 | +36.6% | 0.13% | +22.4% |
| Q2 2019 | $1,994,000 | +60.3% | 307,280 | +75.2% | 0.11% | +50.7% |
| Q1 2019 | $1,244,000 | +86.2% | 175,423 | +27.6% | 0.07% | +44.9% |
| Q4 2018 | $668,000 | -18.8% | 137,497 | +22.9% | 0.05% | +4.3% |
| Q3 2018 | $823,000 | +28.2% | 111,905 | +11.2% | 0.05% | +14.6% |
| Q2 2018 | $642,000 | -46.6% | 100,625 | -54.5% | 0.04% | -48.8% |
| Q1 2018 | $1,202,000 | +33.6% | 220,986 | +2.4% | 0.08% | +40.4% |
| Q4 2017 | $900,000 | +9.9% | 215,760 | +153.6% | 0.06% | +11.8% |
| Q3 2017 | $819,000 | – | 85,083 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 3,365,000 | $16,186,000 | 1.49% |
| CADIAN CAPITAL MANAGEMENT, LP | 5,517,767 | $26,540,000 | 1.17% |
| NEEDHAM INVESTMENT MANAGEMENT LLC | 1,590,000 | $7,646,000 | 1.04% |
| Parkman Healthcare Partners LLC | 420,000 | $2,020,000 | 0.58% |
| Penn Capital Management Company, LLC | 977,526 | $4,702,000 | 0.49% |
| Bullseye Asset Management LLC | 79,272 | $381,000 | 0.37% |
| Bellevue Group AG | 2,441,241 | $11,742,000 | 0.19% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 300,783 | $1,447,000 | 0.18% |
| Granite Investment Partners, LLC | 589,313 | $2,835,000 | 0.13% |
| WRAPMANAGER INC | 68,163 | $328,000 | 0.10% |